ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,965.54
0.28%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Seres Therapeutics Inc (MCRB)

  7. Seres Therapeutics Inc (MCRB) News

Seres Therapeutics (MCRB)

Seres Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MCRB
DateTimeSourceHeadlineSymbolCompany
08/05/202415:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MCRBSeres Therapeutics Inc
08/05/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
08/05/202412:00Business WireSeres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
07/05/202422:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
06/05/202421:01Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
06/05/202414:30Business WireSeres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024NASDAQ:MCRBSeres Therapeutics Inc
09/04/202412:00Business WireSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTNASDAQ:MCRBSeres Therapeutics Inc
28/03/202411:00Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
19/03/202411:00Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
05/03/202415:18Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
05/03/202415:13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MCRBSeres Therapeutics Inc
05/03/202412:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
05/03/202412:00Business WireSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
05/03/202411:05IH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:MCRBSeres Therapeutics Inc
28/02/202412:00Business WireSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024NASDAQ:MCRBSeres Therapeutics Inc
27/02/202412:00Business WireSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
26/02/202412:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
26/02/202412:00Business WireSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzNASDAQ:MCRBSeres Therapeutics Inc
23/02/202421:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
17/02/202402:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
30/01/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
17/01/202412:00Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MCRB

Your Recent History

LSE
PET
Petrel Resources
LSE
VAST
Vast Resources
LSE
TERN
Tern
LSE
SYME
Supply@me Capital
LSE
SCE
Surface Transforms
LSE
SCLP
Scancell
LSE
GKP
Gulf Keystone Petroleum
LSE
POS
Plexus
LSE
AGL
Angle
LSE
BT.A
Bt
LSE
EEE
Empire Metals
LSE
PANR
Pantheon Resources
LSE
OXB
Oxford Biomedica
LSE
ITV
Itv
LSE
GOLD
LSE
SRSP
Sirius Petroleum
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved